pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2–6 (Arm A)	pertuzumab 840 mg q3w for six cycles (Arm B)	The safety profiles	20961	21264	The total number of grade ⩾3 AEs was 78 in Arm A and 60 in Arm B and the most frequent grade ⩾3 AEs are shown in Table 3. Seventy-three percent and 67% of patients in Arms A and B, respectively, experienced at least one serious AE and the total number of all serious AEs was 35 in Arm A and 19 in Arm B.
pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2–6 (Arm A)	pertuzumab 840 mg q3w for six cycles (Arm B)	Partial responses	22356	22593	At the end of cycle 6, a partial response was observed in 12 (86%) and 6 (55%) patients in Arms A and B, respectively, whereas 2 (14%) and 3 (27%) patients, respectively, had stable disease. Two patients in Arm B had progressive disease.
pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2–6 (Arm A)	pertuzumab 840 mg q3w for six cycles (Arm B)	Mean pertuzumab Cmin at day 43	18453	18663	the day 43 mean (s.d.) pertuzumab Cmin in Arms A and B was 40.0 μg ml−1 (17.3) and 62.7 μg ml−1 (29.1), respectively, and the geometric mean Cmin in Arms A and B was 36.8 μg ml−1 and 56.4 μg ml−1, respectively.
pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2–6 (Arm A)	pertuzumab 840 mg q3w for six cycles (Arm B)	The safety profiles	1127	1206	The safety profiles were similar between arms and treatment was well tolerated.
